Financial Gravity Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Financial Gravity Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$1.13K	–	1712
2024 Q1	$1.13K	Sell	1 -1	-50%	-$951	﹤0.01%	730
2023 Q4	$3.03K	Buy	+2	New	+$1.65K	﹤0.01%	668
2021 Q3	$605K	Hold	4	–	–	0.28%	68
2021 Q2	$559K	Buy	+4	New	+$2.03K	0.2%	76
2020 Q4	$10K	Buy	+22	New	+$11.9K	0.01%	179
2019 Q4	$375K	Sell	254 -128	-34%	-$43.1K	0.26%	36
2019 Q3	$106K	Sell	382 -85	-18%	-$25.2K	0.09%	196
2019 Q2	$146K	Sell	467 -100	-18%	-$33.3K	0.12%	184
2019 Q1	$232K	Buy	+567	New	+$233K	0.19%	120
2018 Q3	$226K	Buy	672 +101	+18%	+$38.4K	0.24%	96
2018 Q2	$211K	Sell	571 -143	-20%	-$44.7K	0.2%	102
2018 Q1	$211K	Buy	+714	New	+$248K	0.22%	84

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Financial Gravity Asset Management's REGN Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 1 share — an estimated $1.13K sold.

Financial Gravity Asset Management first reported a position in REGN in Q1 2018 and held it in 12 quarters. The position peaked at $605K in Q3 2021. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

Financial Gravity Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 1 Regeneron Pharmaceuticals share in Q2 2024, an estimated $1.13K.
Financial Gravity Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 12 quarters.
Financial Gravity Asset Management's Regeneron Pharmaceuticals position peaked at $605K in Q3 2021.
1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.